See the latest news and media coverage for LENZ Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Pharmaceutical company commercializing presbyopia eye drops
lenz-tx.comLast updated
In short: LENZ Therapeutics reported strong VIZZ launch sales, licensed VIZZ in Australia/NZ and China, and advanced global regulatory filings.
Total revenue reached $5.5 million, driven by VIZZ product sales and license agreements. The company expanded into new international markets and launched telehealth and TV advertising campaigns.
The board also accepted Zach Scheiner's resignation effective June 30, 2026, reducing the board size to six members without dispute.
George Jeffrey P acquired 22,100 stock options on June 15, 2026, as reported in an SEC Form 4 filing.
Everest acquired rights from Corxel via asset purchase agreement, with NDA submitted in September 2025 and approval anticipated in Q1 2027. LENZ eligible for up to $85 million in milestones plus royalties.
LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported second quarter 2026 results on August 11, 2026, delivering numbers that beat analyst expectations on both the top and...
ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.
The analyst fair value estimate for LENZ Therapeutics has shifted from US$32.00 to about US$26.83...
Lenz Therapeutics (LENZ) stock dips as Bank of America downgrades the firm to Neutral on a...
Track LENZ Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to LENZ Therapeutics and other trending companies.